Once-Daily Oral Dose of BeneFlax to Healthy Older Adults

NCT01846117 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-06-14

No results posted yet for this study

Summary

The investigators are investigating whether the flax lignan, secoisolariciresinol diglucoside, decreases oxidative stress and inflammation. The flax seed lignan is believed to be broken down in the body to produce the health benefits of flax. Flax lignan is separated from the whole flax seed as this compound is believed to have health effects. Decreasing oxidative stress and inflammation should improve a number of the problems associated with aging. This intervention consists of 600 milligrams of the flax lignan SDG daily or an equivalent amount of whey protein.

The investigators are comparing lignan to a placebo (whey powder) to examine whether a dietary intervention (i.e. flax seed containing lignan) might decrease oxidative stress and inflammation.

Conditions

Interventions

DIETARY_SUPPLEMENT

secoisolariciresinol diglucoside, vitamin D

SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors

Sponsors & Collaborators

  • Saskatchewan Health Research Foundation

    collaborator OTHER
  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Jennifer Jones, MD, FRCPC · University of Saskatchewan

  • Jane Alcorn, DVD, PhD · University of Saskatchewan

  • Susan Whiting, PhD · University of Saskatchewan

  • Kerry Mansell, BSP, PharmD · University of Saskatchewan

  • Sharyle Fowler, MD · University of Saskatchewan

  • Lilian Thorpe, MD, PhD · University of Saskatchewan

  • Thomas Hadjistavropoulos, PhD, RD · University of Regina

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2014-11-30
Completion
2014-11-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01846117 on ClinicalTrials.gov